A systematic approach to surgical hemostat use supports standardization and cost efficiencies

by: Nicole Ferko MSc, Cornerstone Research Group, Burlington, ON, Canada
Walt Danker III PhD and Gaurav Gangoli PharmD, Ethicon Inc., Somerville, NJ, USA

Summary
• A systematic approach to bleeding management, the Hemostasis Optimization Program (HOP), was implemented at a large U.S. teaching hospital.
• Implementation of the HOP framework resulted in an annual cost savings of $168,688.
• This evaluation demonstrated that cost savings, as well as operating room and supply chain efficiencies, were achieved without sacrificing patient outcomes.

Surgical bleeding and variability in hemostat utilization
Disruptive bleeding remains a critical challenge in surgery, as it can lead to suboptimal patient outcomes, introduce procedure complexities for surgeons and surgical staff, and result in higher healthcare costs.1,2 For example, uncontrolled bleeding is associated with significantly higher healthcare costs.1 Primary methods of hemostasis, such as electrocautery, sutures, and staples, do not always allow achievement of complete hemostasis, or may be impractical. As such, use of adjunctive topical hemostats may be required to help achieve rapid and effective hemostasis.

Adjunctive hemostats manage bleeding by acting as mechanical barriers, providing a matrix for clotting, triggering coagulation, and/or sealing adjacent surfaces. Compared to primary methods alone, adjunctive hemostats have been shown to reduce utilization of hospital resources: up to 40% fewer patients require blood transfusions, up to 4 days shorter length of stay, up to 25 minutes reduced operating time, and significantly decreased likelihood of hospital readmission.3-6

A wide array of various types of adjunctive hemostats are available (e.g., absorbable matrices, gelatins, fibrin sealants, and patches) to accommodate various needs.7 However, selecting the most appropriate hemostat is challenging given ambiguous bleeding classifications, inconsistent clinical guidance on optimal utilization, and limited indications for use appropriate to specific bleeding situations. These ambiguities can create substantial confusion and potentially unnecessary variability for the management of surgical bleeding, as well as significant clinical and economic hospital burden.

A systematic approach to bleeding management
Because there is no existing universal and practical algorithm that provides guidance for surgical bleeding classification or optimal hemostat utilization, Ethicon, Inc. embarked on a large-scale quantitative research study that characterized hemostat usage. This research involved 450 surgeons from 11 surgical specialties, comprising over 7,800 bleeding occasions. Findings of this endeavor revealed that surgeons’ decisions for hemostat selection rely predominantly on the surgical bleeding site (anatomy and critical surrounding anatomic structures) and situation (access, tissue surface, bleeding intensity, and bleeding risk). Specifically, the real-world data categorized five universal bleeding situations and the optimal adjunctive hemostat selection for each situation. For example, continuous oozing bleeding would most optimally be addressed with oxidized regenerated cellulose (ORC) (see table). This guidance on the use of adjunctive hemostats in each bleeding situation is based on their physical and biochemical properties, mode of action, and real-world experience use across a broad range of surgical specialties.

Using the data and recommendations from this research, the Hemostasis Optimization Program (HOP) was developed, which focuses on reducing variation in hemostat use and optimizing performance in surgical bleeding management. The program was designed to provide guidance on adjunctive hemostat use through a systematic, step-wise approach that evaluates product use and performance, educates surgical teams, and provides action plans for the healthcare facility:
1. Collect and analyze hospital-specific data on case observations and product utilization
2. Review data and generate action plan regarding hemostat utilization education and evaluation with multidisciplinary team
3. Hold education sessions on topics such as the burden of bleeding, hemostat marketplace clarification, science of hemostasis, and the program’s framework and guidance for recommended hemostat use
4. Establish and conduct in-procedure evaluations of the recommended solutions over a set time period
5. Ask surgeons and nursing staff to share experiences and feedback on the program’s effectiveness, as well as hurdles encountered and recommended solutions

As part of the program, several key materials are shared to enhance clinical awareness, including educational modules, procedural bleeding guides, and framework algorithms.

Real-world evidence at a U.S. hospital
The program has been implemented at hospitals across various countries, and the focus of this paper is the program’s impact at a large U.S. teaching hospital. At this hospital, as with most healthcare facilities, optimizing patient outcomes is a top priority. Second to this, cost containment has become essential, with the supply chain team increasingly looking for ways to optimize expenditure without sacrificing patient...
outcomes. With high volume and variability of hemostat use and product expenditure, implementing the HOP program represented a critical opportunity for the hospital to achieve its goal of continuously improving care based on value and quality.

Such goals are aligned with the “Triple Aim,” “Quadruple Aim,” and the increasing push for value-based healthcare. At the hospital, the Supply Chain team, which has the combined role of product value analysis for perioperative products and inventory management, led the implementation of the HOP program and the conversion of the adjunctive hemostat portfolio to the new manufacturer (Ethicon).

A critical first step for the decision to implement the HOP program was to conduct a clinical and cost value analysis on the integration of the new manufacturer’s hemostats. The results of this analysis showed the potential for substantial cost savings, with similar or superior clinical benefits compared with using hemostats from the previous manufacturer. A trial period, then full conversion, of the adjunctive hemostat category was initiated in 2016. Essentially, the process involved switching 95% of the adjunctive hemostat category from prior manufacturers to a full-line supplier. The suite of value-added solutions offered by the HOP program was a key factor in the conversion decision-making process. Consolidating from two manufacturers to predominately one also facilitated more efficient inventory management. Furthermore, converting to a full-line supplier allowed the hospital to have a broader portfolio of products to address their bleeding management needs.

Lessons were learned from this conversion and program implementation. Obtaining surgeon buy-in was critical to the success of this initiative, and the HOP framework facilitated constructive dialogue. Sharing details on the economic evidence was also critical in validating the process, for example, shifting utilization to more cost-effective products. In addition, education on the rationale for conversion, explanation of product differences and advances over time, and product demonstrations were key factors in obtaining buy-in from clinician and non-clinician stakeholders. Importantly, the support and active engagement of the new manufacturer’s representatives, for continual education on the HOP program during procedures and across the surgical community facilitated comprehensive deployment of this initiative.

Once the hospital achieved value analysis and clinician buy-in, the next step was determining how best to customize and integrate the HOP program, which the Supply Chain team felt was the most comprehensive program of its kind seen at their hospital. A hands-on process was required both inside and outside the operating room to bring in training and manage hurdles. The HOP framework was open to all specialties across all operating rooms; the highest level of interest came from cardiothoracic, vascular, spine, and neurosurgery, where multiple hemostats per procedure are sometimes used. Training was provided through various formats to accommodate different needs for the surgeons and staff, including in-services, audiovisual materials, handouts, presentations, and hands-on product training. To help with seamless delivery and minimize interruption, education was offered across shifts and was integrated into the normal workflow; for example, part of the training occurred at weekly staff meetings. Approximately 100 individuals were trained, including surgeons, nurse managers, inventory personnel, and perioperative technicians.

Finally, a system was set up to track hemostat costs as part of the program implementation. The number of hemostat units, by type, was analyzed to determine hemostat expenditure over a one-year observation period. In addition, a team outside of perioperative supply chain services tracked clinical outcomes, which were continuously monitored for changes in the data over time—no differences were detected before versus after conversion and HOP program implementation.

Achieving the goals

The economic analysis of the program’s impact revealed an annual cost savings of $168,688, not including contractual savings from switching to the full-line supplier. These findings aligned with the predicted savings calculated as part of the project’s initiation. To appropriately compare hemostat costs before and after program implementation, it was necessary to control for several factors, including new products introduced that were not part of the initial analysis, contracted price changes, and the case volume increase that occurred over the one-year observation period. Interestingly, the spend per hemostat unit trended downward 15% over the year (see figure), from a higher average to a lower average spend per unit of product, while case volume trended higher. This hemostat spend optimization was enabled by a shift toward the manufacturer’s more cost-effective products appropriate to each bleeding situation, in particular, advanced ORC hemostats (Surgicel SNoW™ Absorbable Hemostat) and optimal utilization of flowable hemostats (Surgiflo® Hemostatic Matrix). These findings indicate that the hospital managed the growth of its resource needs well and increasingly optimized its use of adjunctive hemostats over time.

These cost savings and product utilization efficiencies were observed alongside high surgeon and nurse satisfaction. For instance, it was reported that the team of nurses and surgeons were “Very Satisfied” (on a five-point rating scale) with the success of both product conversion and implementation of the HOP program. The hospital also noted improved product education and enhanced communication and support through a solid partnership with the manufacturer, which was integral to the program’s success. Furthermore, operating room efficiencies were observed, which can be partially attributed to having a predominantly single supplier. From a supply chain perspective, inventory monitoring became easier, contracting became more efficient, product waste was reduced, and higher-priced items were eliminated. Periodic evaluation and maintenance strategies were also put in place to ensure continued success.

Final Words

The Hemostasis Optimization Program was effectively implemented, and it represents one of the most comprehensive programs of its kind by this large U.S. teaching hospital. This evaluation demonstrated that cost savings, as well as operating room and supply chain efficiencies, were achieved without sacrificing patient outcomes. In addition, the portfolio conversion and program implementation were met with high staff satisfaction. Manufacturer support and provision of staff resources, through a consultative partnership, were integral to the success of this value-added initiative. The favorable outcomes of this evaluation warrant further partnership with the manufacturer and evaluation of the HOP program, to improve efficiencies in other applicable medical device categories. HPN

References:
EVITHROM® Thrombin, Topical (Human) for Topical Use Only
Lyophilized Powder for Solution

EVITHROM® is a topical thrombin indicated as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical.

EVITHROM® may be used in conjunction with an Absorbable Gelatin Sponge, USP.

Important Safety Information
• For topical use only.
• Do not inject.
• Apply EVITHROM® on the surface of bleeding tissue only.
• The amount of EVITHROM® required depends upon the area of tissue to be treated and the method of application. In clinical studies, volumes up to 10 ml were used in conjunction with Absorbable Gelatin Sponge.
• Do not use for the treatment of severe or brisk arterial bleeding.
• Do not use in individuals known to have anaphylactic or severe systemic reaction to human blood products. Hypersensitivity reactions, including anaphylaxis, may occur.
• There is a potential risk of thrombosis if absorbed systemically.
• May carry a risk of transmitting infectious agents such as viruses and theoretically, the Creutzfeldt-Jakob disease (CJD) agent, despite manufacturing steps designed to reduce the risk of viral transmission.
• The most common adverse reactions during clinical trial (reported in at least 2% of subjects treated with EVITHROM®) were prolonged activated partial thromboplastin time, increased INR, decreased lymphocyte count, prolonged prothrombin time and increased neutrophil count.
• None of the patients treated with EVITHROM developed antibodies to human thrombin or to human Factor V/Va. The clinical significance of these findings is unknown.

For complete indications, contraindications, warnings, precautions, and adverse reactions, please reference full package insert.

SURGIFLO® Hemostatic Matrix Kit Essential Product Information
(Made from Absorbable Gelatin Sponge, USP) with Thrombin

DESCRIPTION
SURGIFLO® with Thrombin (SURGIFLO® Hemostatic Matrix Kit) is intended for hemostatic use by applying to a bleeding surface.

ACTIONS
When used in appropriate amounts SURGIFLO® is absorbed completely within 4 to 6 weeks.

INTENDED USE/INDICATIONS
SURGIFLO®, mixed with thrombin solution, is indicated in surgical procedures (other than ophthalmic) as an adjunct to hemostasis when control of bleeding by ligature or other conventional methods is ineffective or impractical.

CONTRAINDICATIONS
• Do not use SURGIFLO® in intravascular compartments because of the risk of embolization.
• Do not use SURGIFLO® in patients with known allergies to porcine gelatin.
• Do not use SURGIFLO® in closure of skin incisions because it may interfere with the healing of skin edges. This interference is due to mechanical interposition of gelatin and is not secondary to intrinsic interference with wound healing.

WARNINGS
• SURGIFLO® should not be used in the presence of infection and should be used with caution in contaminated areas of the body.
• SURGIFLO® should not be used in instances of pumping arterial hemorrhage. SURGIFLO® will not act as a tampon or plug in a bleeding site.
• SURGIFLO® should be removed from the site of application when used in, around, or in proximity to foramina in bone, areas of bony confine, the spinal cord, and/or the optic nerve and chiasm because it may swell resulting in nerve damage.
• Excess SURGIFLO® should be removed once hemostasis has been achieved.
• The safety and effectiveness of SURGIFLO® for use in ophthalmic procedures has not been established.
• SURGIFLO® should not be used for controlling post-partum intrauterine bleeding or menorrhagia.
• The safety and effectiveness of SURGIFLO® has not been established in children and pregnant women.
• The blue flexible applicator tip should not be trimmed to avoid exposing internal guidewire.
• The white straight applicator tip should be trimmed away from the surgical area. Cut a square angle to avoid creating a sharp tip.

PRECAUTIONS
• Safe and effective use of SURGIFOAM® Sponge has been reported in a published neurologic retrospective study involving 1700 cases in Europe. Safe and effective use in neurosurgery has not been proven through randomized, controlled clinical studies in the United States.
• SURGIFLO® is supplied as a sterile product and cannot be resterilized.
• SURGIFLO® should not be used for packing unless excess product that is not needed to maintain hemostasis is removed. SURGIFLO® may swell up to 20% upon contact with additional fluid.
• SURGIFLO® should not be used in conjunction with autologous blood salvage circuits.
• SURGIFLO® should not be used in conjunction with methylmethacrylate adhesives.
• In urological procedures, SURGIFLO® should not be left in the renal pelvis or ureters to eliminate the potential foci for calculus formation.
ADVERSE EVENTS
A total of 142 patients received SURGIFOAM® Sponge during a clinical trial comparing SURGIFOAM® Sponge to another absorbable gelatin sponge. In general, the following adverse events have been reported with the use of absorbable porcine gelatin-based hemostatic agents:

- Gelatin-based hemostatic agents may serve as a nidus for infection and abscess formation and have been reported to potentiate bacterial growth.
- Giant cell granulomas have been observed at implant sites when used in the brain.
- Compression of the brain and spinal cord resulting from the accumulation of sterile fluid have been observed.
- Multiple neurologic events were reported when absorbable gelatin-based hemostatic agents were used in laminectomy operations, including cauda equina syndrome, spinal stenosis, meningitis, arachnoiditis, headaches, paresthesias, pain, bladder and bowel dysfunction, and impotence.
- The use of absorbable gelatin-based hemostatic agents during the repair of dural defects associated with laminectomy and craniotomy operations, has been associated with fever, infection, leg paresthesias, neck and back pain, bladder and bowel incontinence, cauda equina syndrome, neurogenic bladder, impotence, and paresis.
- The use of absorbable gelatin-based hemostatic agents has been associated with paralysis, due to device migration into foramina in the bone around the spinal cord, and blindness, due to device migration in the orbit of the eye, during lobectomy, laminectomy, and repair of a frontal skull fracture and lacerated lobe.
- Foreign body reactions, “encapsulation” of fluid, and hematoma have been observed at implant sites.
- Excessive fibrosis and prolonged fixation of a tendon have been reported when absorbable gelatin-based sponges were used in severed tendon repair.
- Toxic shock syndrome was reported in association with the use of absorbable gelatin-based hemostats in nasal surgery.
- Fever, failure of absorption, and hearing loss have been observed when absorbable hemostatic agents were used during tympanoplasty.

SURGICEL Essential Product Information

INDICATIONS
SURGICEL® Absorbable Hemostat (oxidized regenerated cellulose) is used adjunctively in surgical procedures to assist in the control of capillary, venous, and small arterial hemorrhage when ligation or other conventional methods of control are impractical or ineffective. SURGICEL® ORIGINAL, SURGICEL® FIBRILLAR™ and SURGICEL® NU-KNIT® Hemostats can be cut to size for use in endoscopic procedures.

PRECAUTIONS
- Use only as much SURGICEL® Absorbable Hemostat as is necessary for hemostasis, holding it firmly in place until bleeding stops. Remove any excess before surgical closure in order to facilitate absorption and minimize the possibility of foreign body reaction.
- In urological procedures, minimal amounts of SURGICEL® Absorbable Hemostat should be used and care must be exercised to prevent plugging of the urethra, ureter, or a catheter by dislodged portions of the product.
- Since absorption of SURGICEL® Absorbable Hemostat could be prevented in chemically cauterized areas, its use should not be preceded by application of silver nitrate or any other escharotic chemicals.
- If SURGICEL® Absorbable Hemostat is used temporarily to line the cavity of large open wounds, it should be placed so as not to overlap the skin edges. It should also be removed from open wounds by forceps or by irrigation with sterile water or saline solution after bleeding has stopped.
- Precautions should be taken in otorhinolaryngologic surgery to assure that none of the material is aspirated by the patient. (Examples: controlling hemorrhage after tonsillectomy and controlling epistaxis.)
- Care should be taken not to apply SURGICEL® Absorbable Hemostat too tightly when it is used as a wrap during vascular surgery (see Adverse Reactions).

ADVERSE EVENTS
- “Encapsulation” of fluid and foreign body reactions have been reported.
- There have been reports of stenotic effect when SURGICEL® Absorbable Hemostat has been applied as a wrap during vascular surgery.
- Paralysis and nerve damage have been reported when SURGICEL® Absorbable Hemostat was used around, in, or in proximity to foramina in bone, areas of bony confine, the spinal cord, and/or the optic nerve and chiasm.
- Blindness has been reported in connection with surgical repair of a lacerated left frontal lobe when SURGICEL® Absorbable Hemostat was placed in the anterior cranial fossa.
- Possible prolongation of drainage in cholecystectomies and difficulty passing urine per urethra after prostatectomy have been reported.

For more information, please consult your doctor or for product quality and technical questions, call 1-800-795-0012.
SURGIFOAM® Hemostatic Matrix Kit

(Also Available as Absorbable Gelatin Sponge, SPS) with Thrombin

Caution: Federal (U.S.A.) law restricts this device to sale only on or by the order of a physician (or properly licensed practitioner).

Do not inject into blood vessels.

DESCRIPTION

SURGIFOAM® Hemostatic Matrix Kit with Thrombin (SURGIFOAM® Hemostatic Matrix Kit) is intended for hemostatic use by applying to a bleeding surface.

The Kit components are:

1. A sterile tray with all solution components to prepare the SURGIFOAM® Matrix, a sterile tray with all solution components to prepare the Thrombin Solution.
2. The SURGIFOAM® Matrix comes in a tray with all sterile components:
   - A pre-filled plunger syringe containing the porous Gelatin Matrix that is off-white in appearance.
   - A sterile empty syringe.
   - A sterile liquid transfer cap.
   - A sterile rubber band that is usable in all directions, and
   - A sterile white applicator tip that can be trimmed to desired length.
3. The surface sterile components to prepare the Thrombin Solution include:
   - A sterile, single-use ENDOTRACHEAL INTUBATION TRAY containing 2000 International Units (IU) of topical human thrombin (type II) powder for reconstitution.
   - A needle-free syringe containing 2 mL of Sterile Water for Injection (Sterile Water). A sterile needle and syringe for reconstitution.

For prescribing information on the components, please refer to the ENDOTRACHEAL INTUBATION TRAY, Topical (Human) Prescribing Information on page 9.

Thrombin should be used with the reconstituted needle and the syringe with Sterile Water with Ethyl Alcohol 5% and Sterile Water (Injection).

The Thrombin Solution should be added to the SURGIFOAM® Matrix prior to use. The correct amount of Thrombin Solution should be attached to the syringe for product delivery onto the bleeding site.

ACTIONS

SURGIFOAM® Hemostatic Matrix Kit has hemostatic properties. When used in appropriate amounts and hemostatic use by applying to a bleeding surface.

The SURGIFOAM® Hemostatic Matrix Kit with Thrombin (SURGIFOAM® Hemostatic Matrix Kit) is intended for:

- The control of bleeding by ligature or other conventional procedures for hemostasis.
- The control of bleeding when control of bleeding by ligature or other conventional procedures is not adequate. Thrombin is an adjunct to hemostasis when control of bleeding by ligature or other conventional procedures is not adequate.

SURGIFOAM® Hemostatic Matrix Kit is indicated for surgical procedures (other than ophthalmic) as an adjunct to hemostasis when control of bleeding by ligature or other conventional procedures is not adequate.

The SURGIFOAM® Hemostatic Matrix is absorbed completely within 4 to 6 weeks. In an animal implantation study, the SURGIFOAM® Hemostatic Matrix was absorbed completely within 4 to 6 weeks. The SURGIFOAM® Hemostatic Matrix Kit has hemostatic properties. When used in appropriate amounts and hemostatic use by applying to a bleeding surface.

Once the hemostatic matrix is mixed with the Thrombin Solution, the appropriate applicator tip should be attached to the syringe for product delivery onto the bleeding site.

Thrombin should be reconstituted using the vial adapter and the needle-free syringe with Sterile Water for Injection. A sterile tray with all solution components to prepare the Thrombin Solution.

Table 1 lists those adverse events that occurred in greater than 5% of the SURGIFOAM® Sponge patients. The adverse events observed in greater than 5% of the patients were:

- Headache
- Pain
- Hypotension
- Hypertension
- Infection
- Erythema
- Hemorrhage
- Hypokalemia
- Hypocalcemia
- Asthenia
- Infusion Site Reactions
- Leg Pain

The use of absorbable gelatin-based hemostatic agents during the repair of dural defects associated with laminectomy and craniotomy operations, has been associated with fever, infection, leg pain, and the optic nerve and vision loss. Care should be exercised to avoid overseeing. SURGIFOAM® Hemostatic Matrix may swell, creating the possibility of dislodgment of the device or compression of other nearby anatomic structures.

- The safety and effectiveness of SURGIFOAM® Hemostatic Matrix are intended for use in patients who have been screened for and have no history of a history of or low creatinine clearance.

The use of absorbable gelatin-based hemostatic agents during the repair of dural defects associated with laminectomy and craniotomy operations, has been associated with fever, infection, leg pain, and the optic nerve and vision loss. Care should be exercised to avoid overseeing. SURGIFOAM® Hemostatic Matrix may swell, creating the possibility of dislodgment of the device or compression of other nearby anatomic structures.

- The safety and effectiveness of SURGIFOAM® Hemostatic Matrix are intended for use in patients who have been screened for and have no history of a history of or low creatinine clearance.

The use of absorbable gelatin-based hemostatic agents during the repair of dural defects associated with laminectomy and craniotomy operations, has been associated with fever, infection, leg pain, and the optic nerve and vision loss. Care should be exercised to avoid overseeing. SURGIFOAM® Hemostatic Matrix may swell, creating the possibility of dislodgment of the device or compression of other nearby anatomic structures.

- The safety and effectiveness of SURGIFOAM® Hemostatic Matrix are intended for use in patients who have been screened for and have no history of a history of or low creatinine clearance.

The use of absorbable gelatin-based hemostatic agents during the repair of dural defects associated with laminectomy and craniotomy operations, has been associated with fever, infection, leg pain, and the optic nerve and vision loss. Care should be exercised to avoid overseeing. SURGIFOAM® Hemostatic Matrix may swell, creating the possibility of dislodgment of the device or compression of other nearby anatomic structures.

- The safety and effectiveness of SURGIFOAM® Hemostatic Matrix are intended for use in patients who have been screened for and have no history of a history of or low creatinine clearance.

The use of absorbable gelatin-based hemostatic agents during the repair of dural defects associated with laminectomy and craniotomy operations, has been associated with fever, infection, leg pain, and the optic nerve and vision loss. Care should be exercised to avoid overseeing. SURGIFOAM® Hemostatic Matrix may swell, creating the possibility of dislodgment of the device or compression of other nearby anatomic structures.

- The safety and effectiveness of SURGIFOAM® Hemostatic Matrix are intended for use in patients who have been screened for and have no history of a history of or low creatinine clearance.

The use of absorbable gelatin-based hemostatic agents during the repair of dural defects associated with laminectomy and craniotomy operations, has been associated with fever, infection, leg pain, and the optic nerve and vision loss. Care should be exercised to avoid overseeing. SURGIFOAM® Hemostatic Matrix may swell, creating the possibility of dislodgment of the device or compression of other nearby anatomic structures.

- The safety and effectiveness of SURGIFOAM® Hemostatic Matrix are intended for use in patients who have been screened for and have no history of a history of or low creatinine clearance.

The use of absorbable gelatin-based hemostatic agents during the repair of dural defects associated with laminectomy and craniotomy operations, has been associated with fever, infection, leg pain, and the optic nerve and vision loss. Care should be exercised to avoid overseeing. SURGIFOAM® Hemostatic Matrix may swell, creating the possibility of dislodgment of the device or compression of other nearby anatomic structures.

- The safety and effectiveness of SURGIFOAM® Hemostatic Matrix are intended for use in patients who have been screened for and have no history of a history of or low creatinine clearance.

The use of absorbable gelatin-based hemostatic agents during the repair of dural defects associated with laminectomy and craniotomy operations, has been associated with fever, infection, leg pain, and the optic nerve and vision loss. Care should be exercised to avoid overseeing. SURGIFOAM® Hemostatic Matrix may swell, creating the possibility of dislodgment of the device or compression of other nearby anatomic structures.

- The safety and effectiveness of SURGIFOAM® Hemostatic Matrix are intended for use in patients who have been screened for and have no history of a history of or low creatinine clearance.

The use of absorbable gelatin-based hemostatic agents during the repair of dural defects associated with laminectomy and craniotomy operations, has been associated with fever, infection, leg pain, and the optic nerve and vision loss. Care should be exercised to avoid overseeing. SURGIFOAM® Hemostatic Matrix may swell, creating the possibility of dislodgment of the device or compression of other nearby anatomic structures.

- The safety and effectiveness of SURGIFOAM® Hemostatic Matrix are intended for use in patients who have been screened for and have no history of a history of or low creatinine clearance.

The use of absorbable gelatin-based hemostatic agents during the repair of dural defects associated with laminectomy and craniotomy operations, has been associated with fever, infection, leg pain, and the optic nerve and vision loss. Care should be exercised to avoid overseeing. SURGIFOAM® Hemostatic Matrix may swell, creating the possibility of dislodgment of the device or compression of other nearby anatomic structures.

- The safety and effectiveness of SURGIFOAM® Hemostatic Matrix are intended for use in patients who have been screened for and have no history of a history of or low creatinine clearance.
Study Design: This was a multi-center, prospective, single-arm study. Thirty (30) subjects from three (30) centers undergoing endoscopic sinus surgery (ESS), who met the eligibility criteria, were treated with SURGIFLO® Hemostatic Matrix and Sinus Thrombin past 150. Subjects were followed at 7 days (± 3 days) and at 30 days (± 7 days) post-operatively. In each study, a single-arm study with no control arm. Subjects were followed for 30 days following surgery. Psychometric testing and all complications were recorded during this period.

Study Results: Intranasal bleeding ceased in 29 of 30 patients. One subject failed to achieve hemostasis within 10 minutes of product application. The median time to hemostasis was 14.8 operated sites, including maxillary sinus, was 61 seconds. One patient had mild oozing after surgery. This patient was on local care with immediate resolution. No intraoperative complications, serious adverse events, or serious complications such as septum perforations or infections were reported in this study.

HOW SUPPLIED
SURGIFLO® Hemostatic Matrix Kit consists of:

1. A sterile tray with all sterile components to prepare the Flowable Gelatin Matrix
2. A sterile tray with all sterile components to prepare the Thrombin Solution

SURGIFLO® Hemostatic Matrix Kit is provided in the configuration shown in the table below.

<table>
<thead>
<tr>
<th>Flowable Gelatin Matrix Components</th>
<th>Thrombin Components</th>
</tr>
</thead>
<tbody>
<tr>
<td>• A sterile pre-filled syringe with blue plunger containing the sterile Gelatin Matrix. The syringe is labeled: SURGIFLO® Hemostatic Matrix</td>
<td>• A sterile empty syringe</td>
</tr>
<tr>
<td>• A sterile liquid transfer cup</td>
<td>• A sterile liquid transfer cup</td>
</tr>
<tr>
<td>• A sterile blue flexible applicator tip that is bendable in all directions</td>
<td>• A needle-free syringe containing 2 mL of Sterile Water for Injection (Sterile WFI)</td>
</tr>
<tr>
<td>• A sterile white applicator tip that can be trimmed to desired length</td>
<td>• A sterile vial adapter</td>
</tr>
</tbody>
</table>

The package also contains the SURGIFLO® Hemostatic Matrix Kit Instructions for Use and a labeling guide.

STORAGE AND HANDLING
SURGIFLO® Hemostatic Matrix Kit should be stored dry at controlled room temperature 16°-27°C (60°-80°F).

The Flowable Gelatin Matrix may be used up to eight (8) hours after mixing with the Thrombin Solution.

For prescribing information on the thrombin component, please refer to the ETVI-FRO® Thrombin, Topical (Human) Prescribing Information on page 9.

SURGIFLO® Hemostatic Matrix Kit is for single use only.

DIRECTIONS FOR USE

Before use:

1. Inspect the packages for signs of damage. If the package is damaged or wet, sterility cannot be assured and the contents should not be used.
2. Open packages of SURGIFLO® Hemostatic Matrix Kit should be discarded, since they are not intended for reuse and/or re-sterilization.

Opening the tray with Flowable Gelatin Matrix and tray with Thrombin component:

Open the outer packages and deliver the sterile inner trays to the sterile field using aseptic technique.

Once placed in the sterile field, the sterile inner trays may be removed.

Preparing the Thrombin Solution inside the sterile field:

1. Place the Thrombin vial on a flat surface, put the rubber stopper and the vial adapter on the center of the rubber stopper and push down until the spike penetrates the rubber stopper and the vial adapter options to receive the sterile solution. Remove the sterile adapter.
2. Draw up the Thrombin Solution into the sterile syringe containing the Sterile Water for Injection (Sterile WFI).
3. Connect and screw on the needle-free syringe containing the Sterile Water for Injection (Sterile WFI).
4. Gently swirl the Thrombin vial until the Thrombin Solution is clear.
5. Draw up the Thrombin Solution into the needle-free syringe. Label the needle-free syringe “Thrombin 2000 IU.”
6. Disconnect the needle-free syringe from the vial adapter and transfer the Thrombin Solution into the sterile liquid transfer cup as shown in the next section (Figure 1).

After reconstitution, discard the components used for the thrombin reconstitution.

Alternatively, the thrombin may be reconstituted outside the sterile field for careful not to touch the rubber stopper of the vial after reconstitution the Thrombin Solution should be transferred into the sterile liquid transfer cup using aseptic technique.

Place the sterile liquid transfer cup near the edge of the sterile field to receive the Thrombin Solution transfer without contaminating the sterile field.

Preparing the Flowable Gelatin Matrix inside the sterile field:

1. Draw up 2 mL of sterile Thrombin Solution from the sterile liquid transfer cup into the empty sterile syringe.
2. Connect syringes

3. Mix contents of the two syringes

Begin mixing by transferring the sterile Thrombin Solution into the sterile pre-filled syringe containing the Gelatin Matrix. Push the combined material back and forth 6 times until the consistency is even.

Once mixed, the thrombotic matrix should be applied completely to the syringe with the blue plastic that is labeled SURGIFLO® Hemostatic Matrix. Remove the empty syringe and discard.

For endoscopic and/or laparoscopic surgical procedures:

a. Prepare the selected endoscope applicator according to the product’s labeling.

b. Attach the selected endoscope applicator tip to the SURGIFLO® Hemostatic Matrix syringe. Make sure that the luer connection is secure.

c. Express SURGIFLO® Hemostatic Matrix from the end of the syringe. Insert the cannula at the lesion. Insert the cannula using caution not to expose SURGIFLO® Hemostatic Matrix.

d. Carefully position the distal end of the endoscopic applicator to the site where SURGIFLO® Hemostatic Matrix is to be delivered. Be careful to avoid damaging tissue with the cannula.

e. While holding the endoscopic applicator in place, express SURGIFLO® Hemostatic Matrix to the bleeding site.

f. If applicable, detach SURGIFLO® Hemostatic Matrix syringe and introduce the stilet to dispense remaining product in the length of the cannula.

g. Observe bleeding and repeat application of SURGIFLO® Hemostatic Matrix if necessary.

h. Carefully remove the endoscopic applicator from the tissue post-syringe. SURGIFLO® Hemostatic Matrix has been delivered to the bleeding site.

For endoscopic sinus surgery and epistaxis:

1. Delivered SURGIFLO® Hemostatic Matrix to the source of bleeding using the selected applicator tip attached to the syringe labeled SURGIFLO® Hemostatic Matrix.

2. Apply sufficient SURGIFLO® Hemostatic Matrix to cover the entire bleeding surface. Using forceps, grasp the appropriate instrument, carefully lay a sterile saline moistened gauze over the SURGIFLO® Hemostatic Matrix for 1-2 minutes to ensure the material remains in contact with the bleeding tissue.

3. In cases of persistent bleeding, indicated by saturation and bleeding through the material, insert the applicator tip through the center of the mass of previously placed SURGIFLO® Hemostatic Matrix to deliver fresh material as close as possible to the tissue surface. After reapplication of SURGIFLO® Hemostatic Matrix, use a sterile saline moistened gauze to approximate the material to the tissue for another minute, and then inspect tissue for further bleeding.

4. Once hemostasis has been achieved, remove the gauze. If possible, excess SURGIFLO® Hemostatic Matrix should be removed with gentle irrigation or cautery scissors. Avoid disrupting the SURGIFLO® Hemostatic Matrix clot complex. The remaining SURGIFLO® Hemostatic Matrix does not have to be removed, as it will be bioabsorbed.

5. Use of visual packing is not necessary when satisfactory hemostasis is achieved.

6. If necessary, gentle irrigation and/or cautery can be used in the post-operative period to remove the remaining SURGIFLO® Hemostatic Matrix.

Caution: The use of SURGIFLO® Hemostatic Matrix for surgical management has not been studied.

Caution: Federal (U.S.A.) law restricts this device to sale by or on the order of a physician (or properly licensed practitioner).

One or more of the authors is a Johnson & Johnson employee. The article was funded by Johnson & Johnson Medical Devices.

08232-171014